-
![2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE](/abs-image/US/2019/04/25/US20190119246A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190119246A1
公开(公告)日：2019-04-25
申请号：US16220963
申请日：2018-12-14
Applicant: Genentech, Inc.
Inventor： James John Crawford , Aleksandr Kolesnikov , Jianwen A. Feng
IPC: C07D401/10
Abstract: The invention relates to compounds of formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20150065482A1
公开(公告)日：2015-03-05
申请号：US14466153
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D401/14 , C07D413/10 , C07D491/052 , C07D487/04 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
Abstract translation: 本发明涉及式（O）的化合物：其中Q，A1-A8，R4和R5各自具有如本文所述的含义。 式（0）的化合物及其药物组合物可用于治疗其中观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
![2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use](/abs-image/US/2020/05/19/US10654824B2/abs.jpg.150x150.jpg)
公开(公告)号：US10654824B2
公开(公告)日：2020-05-19
申请号：US16220963
申请日：2018-12-14
Applicant: Genentech, Inc.
Inventor： James John Crawford , Aleksandr Kolesnikov , Jianwen A. Feng
IPC: C07D401/10
Abstract: The invention relates to compounds of formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20160200739A1
公开(公告)日：2016-07-14
申请号：US15074100
申请日：2016-03-18
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D401/14 , C07D413/14 , C07D471/04 , C07D413/10 , C07D401/10 , C07D403/10 , C07D491/052
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20170210724A1
公开(公告)日：2017-07-27
申请号：US15481852
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Xingyu Lin , Jason Burch
IPC: C07D401/10 , C07D401/14 , C07D491/107 , C07D409/14 , C07D405/14 , C07D495/04 , C07D495/06 , C07D471/04 , C07D487/04 , C07D413/10 , C07D403/10 , C07D405/10 , C07D417/14 , C07D491/048 , C07D413/14
CPC classification number: C07D401/10 , A61K31/395 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107 , C07D495/04 , C07D495/06
Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
Patent Agency Ranking
公开(公告)号：US20170145034A1
公开(公告)日：2017-05-25
申请号：US15425698
申请日：2017-02-06
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D401/14 , C07D491/052 , C07D471/04 , C07D413/10 , C07D491/048 , C07D403/14 , C07D413/14 , C07D495/04 , C07D487/04 , C07D417/10 , C07D403/10 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20160096850A9
公开(公告)日：2016-04-07
申请号：US14466153
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D401/14 , C07D413/10 , C07D491/052 , C07D487/04 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
![2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use](/abs-image/US/2020/02/04/US10550117B2/abs.jpg.150x150.jpg)
公开(公告)号：US10550117B2
公开(公告)日：2020-02-04
申请号：US16221274
申请日：2018-12-14
Applicant: Genentech, Inc.
Inventor： James John Crawford , Aleksandr Kolesnikov , Jianwen A. Feng
IPC: C07D471/04 , C07D417/10 , A61P27/14 , A61P37/06 , A61P17/00 , A61P19/02 , A61P1/00 , A61P11/00
Abstract: The invention relates to compounds of formula (I): wherein Q, A1, A2, A3, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US09605005B2
公开(公告)日：2017-03-28
申请号：US15074100
申请日：2016-03-18
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D401/00 , C07D513/04 , C07D401/14 , C07D413/14 , C07D401/10 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20150057260A1
公开(公告)日：2015-02-26
申请号：US14466176
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Xingyu Lin , Jason Burch
IPC: C07D495/04 , C07D403/10 , C07D405/14 , C07D409/14 , C07D491/107 , C07D403/14 , C07D401/10
CPC classification number: C07D401/10 , A61K31/395 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107 , C07D495/04 , C07D495/06
Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
Abstract translation: 本发明涉及式（O）的化合物：其中A1-A8，R4和R5各自具有如本文所述的含义。 式（0）的化合物及其药物组合物可用于治疗其中观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.033 seconds)
